LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation

Prior treatment

• Patients with known microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR) who are suitable for immune checkpoint inhibitor therapy as assessed by the investigator;
• Patients who did not recover from the AE of previous anti-tumor treatment to ≤ Grade 1;
• Current or previous uncontrolled concomitant non-gastrointestinal disease including, but not limited to myocardial infarction, unstable angina, coronary artery/peripheral artery bypass grafting, heart failure, cerebrovascular accident, transient ischemic attack, pulmonary embolism, deep vein thrombosis, serious arrhythmia, current uncontrolled hypertension, previous history of hypertensive crisis or hypertensive brain disease, tumor invasion into major blood vessels, interstitial lung disease, interstitial pneumonia, pulmonary interstitial fibrosis, reversible posterior leukoencephalopathy syndrome (RPLS), etc.;
• Current or past presence of the gastrointestinal abnormalities, including but not limited to active peptic ulcer, clinically significant gastrointestinal abnormalities prior to informed consent, active colitis, long-term anticoagulant therapy, antiplatelet therapy, etc.;
• Use of prohibited medication or therapy within the specified time;
• Known hypersensitivity to any component of any investigational product;

Other illness

• Malignant tumors other than mCRC within 5 years before signing the informed consent;
• Symptomatic brain metastasis, history of spinal cord compression or meningeal metastasis;
• Underwent other therapeutic surgery other than diagnosis, biopsy, drainage, or expected to require major surgery during the study, or had unhealed wound, ulcer or fracture.
• Current or past significant risk of bleeding;
• History of drug abuse or alcoholism;
• Other conditions that may increase the risk of the study or interfere with study results, in the judgment of the investigator.

Other

• Patients with body cavity effusion requiring local treatment or poorly controlled effusion;
• Pregnant and lactating women;

• Able to provide a signed informed consent;
• Age ≥ 18 years and ≤ 75 years, both male and female;
• Histologically confirmed metastatic colorectal cancer (CRC) with RAS mutation;
• Prior therapies for colorectal cancer:
  • (1 ) For phase 1b patients: who have failed or intolerable to prior first-line therapy; (2) For phase 2 patients: who have not received prior systemic therapy for metastatic colorectal cancer.
  • 5\. At least one measurable lesion according to RECIST 1.1 criteria; 6. Eastern Cooperative Oncology Group (ECOG) score of 0 or 1; 7. Life expectancy≥ 6 months; 8. Adequate bone marrow and organ function; 9. Negative pregnancy test for women of childbearing potential. patients of childbearing potential should take effective contraceptive measures during study drug treatment and until 6 months after initiation of investigational product.